Ward A
Biomedicines. 2025; 13(2).
PMID: 40002910
PMC: 11853056.
DOI: 10.3390/biomedicines13020497.
Orbaugh K, Cuellar S, Sheldon L
J Adv Pract Oncol. 2025; 1-15.
PMID: 39802536
PMC: 11715408.
DOI: 10.6004/jadpro.2024.15.8.5.
Feng J, Zhang M, Ren H, Ren Y, Hao Z, Bian S
Mol Cell Biochem. 2024; .
PMID: 39613944
DOI: 10.1007/s11010-024-05156-0.
Ngule C, Shi R, Ren X, Jia H, Oyelami F, Li D
Mol Cancer. 2024; 23(1):188.
PMID: 39243032
PMC: 11378519.
DOI: 10.1186/s12943-024-02102-y.
Jia H, Liang L, Chen X, Zha W, Diao W, Zhang W
Front Oncol. 2024; 14:1380195.
PMID: 39224807
PMC: 11366635.
DOI: 10.3389/fonc.2024.1380195.
Patterns of fluoroquinolone utilization and resistance in a tertiary care hospital: a retrospective cross-sectional analysis study from a developing country.
Aiesh B, Zuhour A, Omar M, Hamad M, Abutaha A, Al-Jabi S
BMC Infect Dis. 2024; 24(1):856.
PMID: 39179971
PMC: 11342551.
DOI: 10.1186/s12879-024-09749-4.
Current advance of nanotechnology in diagnosis and treatment for malignant tumors.
Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y
Signal Transduct Target Ther. 2024; 9(1):200.
PMID: 39128942
PMC: 11323968.
DOI: 10.1038/s41392-024-01889-y.
Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions.
Li S, Wang H, Xiong S, Liu J, Sun S
Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065683
PMC: 11279695.
DOI: 10.3390/ph17070832.
Cholecystocutaneous Fistula Associated with Edwardsiella tarda as a Result of Aggressive Lymphoma Development.
Masuda Y, Honda A, Matsumoto S, Yamamoto S, Tanaka M, Tsutsumi T
Intern Med. 2024; 64(3):429-433.
PMID: 38925971
PMC: 11867751.
DOI: 10.2169/internalmedicine.3851-24.
Neutrophils in Cancer immunotherapy: friends or foes?.
Huang X, Nepovimova E, Adam V, Sivak L, Heger Z, Valko M
Mol Cancer. 2024; 23(1):107.
PMID: 38760815
PMC: 11102125.
DOI: 10.1186/s12943-024-02004-z.
The Real-Life Impact of Primary Tumor Resection of Synchronous Metastatic Colorectal Cancer-From a Clinical Oncologic Point of View.
Pecsi B, Mangel L
Cancers (Basel). 2024; 16(8).
PMID: 38672540
PMC: 11047864.
DOI: 10.3390/cancers16081460.
Chemotherapy activates inflammasomes to cause inflammation-associated bone loss.
Wang C, Kaur K, Xu C, Abu-Amer Y, Mbalaviele G
Elife. 2024; 13.
PMID: 38602733
PMC: 11008812.
DOI: 10.7554/eLife.92885.
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.
Kayki-Mutlu G, Aksoyalp Z, Wojnowski L, Michel M
Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(5):2949-2970.
PMID: 38530400
PMC: 11074039.
DOI: 10.1007/s00210-024-03063-1.
Designing a green poly(β-amino ester) for the delivery of nicotinamide drugs with biological activities and conducting a DFT investigation.
Hashem M, Fahim A, Helaly F
RSC Adv. 2024; 14(8):5499-5513.
PMID: 38352682
PMC: 10862102.
DOI: 10.1039/d3ra08585f.
Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth.
Bodac A, Mayet A, Rana S, Pascual J, Bowler A, Roh V
EMBO Mol Med. 2024; 16(1):158-184.
PMID: 38177532
PMC: 10897164.
DOI: 10.1038/s44321-023-00013-x.
Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy.
Bachlitzanaki M, Aletras G, Bachlitzanaki E, Messaritakis I, Koukias S, Koulouridi A
Microorganisms. 2023; 11(10).
PMID: 37894205
PMC: 10609470.
DOI: 10.3390/microorganisms11102547.
Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
Aapro M, Chaplin S, Cornes P, Howe S, Link H, Koptelova N
Support Care Cancer. 2023; 31(10):581.
PMID: 37728795
PMC: 10511548.
DOI: 10.1007/s00520-023-08043-4.
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
Jiang Y, Zhang J, Zhong J, Liao H, Zhang J, Liu Y
BMC Cancer. 2023; 23(1):702.
PMID: 37495949
PMC: 10373237.
DOI: 10.1186/s12885-023-11198-2.
Efbemalenograstim Alfa: First Approval.
Blair H
Drugs. 2023; 83(12):1125-1130.
PMID: 37368138
DOI: 10.1007/s40265-023-01911-7.
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
Kayki-Mutlu G, Aksoyalp Z, Wojnowski L, Michel M
Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(8):1619-1632.
PMID: 36951997
PMC: 10034907.
DOI: 10.1007/s00210-023-02465-x.
